Immunovia

    OverviewSuggest Edit

    Immunovia engages in the development of a technology platform based on antibody microarray analysis. It focuses on developing diagnosis of cancer and autoimmune diseases. The Company offers IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. It also provides IMMray Proteome Survey platform, a discovery tool for proteome scanning. 

    TypePublic
    Founded2007
    HQLund, SE
    Websiteimmunovia.com

    Latest Updates

    Employees (est.) (Feb 2019)45(+5%)

    Key People/Management at Immunovia

    Rolf Ehrnström

    Rolf Ehrnström

    Chief Scientific Officer
    Hans Liljenborg

    Hans Liljenborg

    CFO
    Laura Chirica

    Laura Chirica

    Chief Commercial Officer
    Henrik Winther

    Henrik Winther

    SVP Business Development
    Linda Mellby

    Linda Mellby

    Development Director
    Show more

    Immunovia Office Locations

    Immunovia has an office in Lund
    Lund, SE (HQ)
    Medicon Village Scheelevägen 2
    Show all (1)

    Immunovia Online and Social Media Presence

    Embed Graph

    Immunovia News and Updates

    Immunovia - Report from AGM

    STOCKHOLM, April 26, 2019 /PRNewswire/ -- The Annual General Meeting (AGM) of Immunovia AB (publ), corporate identity number 556730-4299 was held at Gamla Gästmatsalen in Medicon Village, Scheelevägen 2, Lund, Sweden on April 26 2019. A summary of the Meeting's resolutions follows:...

    Immunovia Interim Report, January-March 2019

    STOCKHOLM, April 24, 2019 /PRNewswire/ -- During the first quarter of 2019, we remained focused on our product launch strategy and continued to create value, as we reached several key objectives and took several steps towards the commercialization of IMMray™ PanCan-d, our diagnostic test...

    Immunovia and University College of London Sign Agreement to Extend Validation Studies of IMMray™ PanCan-d for Early Signs and Symptoms

    LUND, Sweden, April 8, 2019 /PRNewswire/ -- Immunovia today announced that Prof. Stephen Pereira and his team at the institute for Liver and Digestive Health, University College London (UCL) will extend the prospective collection of blood samples funded by Immunovia and that started with...

    Immunovia Publishes the Annual Report for the Financial Year 2018

    LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website. Mats Grahn, CEO, comments: "We entered 2018 with the continued mission to develop and validate accurate blood-based diagnostic tests and ...

    Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray™ PanCan-d

    LUND, SWEDEN, March 4, 2019 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced an update on the optimization process to refine the algorithms and eliminate any potential variations for its commercial version of IMMray™ PanCan-d designed for early detection of pancreatic...

    Immunovia Full Year Report, January-December 2018

    STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- Throughout 2018, we continued to build on our mission to develop and validate accurate bloodbased diagnostic tests that can make a real and significant impact on healthcare worldwide and to initiate the exciting activities to commercialize those...
    Show more

    Immunovia Blogs

    Immunovia’s pancreatic cancer awareness campaign airs in Times Square, New York City

    Immunovia’s new video, highlighting the importance of early detection in pancreatic cancer, will air today in the heart of Times Square in New York City. The campaign will run approximately three times an hour through September 30, 2019 on the “Bowtie Screen” located at the corner of 1500 Broadway a…

    Poster presentation: Differentiating Pancreatic Ductal Adenocarcinoma (PDAC) from individuals with symptoms suggestive of PDAC, including type II diabetes, with ROC AUC values above 0.95

    Payam Delfani, Anders Carlsson, Thomas King, Alexander Ney, Stephen P Pereira, Linda Dexlin Mellby IMMray™ PanCan-d poster presentation at the PancreasFest 2019, Pittsburgh (PA), USA, July 24-26, 2019 Click here to read the complete poster (pdf). Link to press release from July 11, 2019. The post Po…

    ACS 2018 Cancer Facts & Figures Highlights the Urgent Need for Early Detection Tools and Effective Treatments in Pancreatic Cancer

    The American Cancer Society (ACS) recently released updated Cancer Facts & Figures report, providing a snapshot of American cancer statistics and predictions across all cancer sites. In the US, the ACS estimates there will be 56,770 people diagnosed with pancreatic cancer and 45,750 deaths from …

    In 2018, Immunovia reached over 24,000 people through 24 Walks in 15 US states

    Beginning in April 2018, Immunovia partnered with several prominent patient organizations by sponsoring pancreatic cancer walks across the United States. Organized nationally throughout the year, these walks increase awareness about the disease and raise money for research. The walks also allow peop…

    Nobel Laureates’ visit has special significance for Immunovia

    Following the official ceremony in Stockholm, the shared winners of this year’s Nobel Prize in Chemistry, George P. Smith and Sir Gregory P. Winter, visited Medicon Valley to give inspiring presentations on their pioneering work in developing ways of producing human antibodies, the proteins produced…

    Year End message from Immunovia´s CEO Mats Grahn

    As the snow falls over Immunovia’s facilities in Lund, Sweden and Marlborough, USA, season’s greetings from all of us! We’d like to invite all of our investors, collaborators, supporters and suppliers to join in celebrating what has been a year of great progress. Over the last year, we have continue…
    Show more

    Immunovia Frequently Asked Questions

    • When was Immunovia founded?

      Immunovia was founded in 2007.

    • Who are Immunovia key executives?

      Immunovia's key executives are Rolf Ehrnström, Hans Liljenborg and Laura Chirica.

    • How many employees does Immunovia have?

      Immunovia has 45 employees.

    • Who are Immunovia competitors?

      Competitors of Immunovia include Guardant Health, Personalis and ClinSpec.

    • Where is Immunovia headquarters?

      Immunovia headquarters is located at Medicon Village Scheelevägen 2, Lund.

    • Where are Immunovia offices?

      Immunovia has an office in Lund.

    • How many offices does Immunovia have?

      Immunovia has 1 office.